FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours por rosponso:	Λ.Ε.								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Haley Patrick J.						2. Issuer Name and Ticker or Trading Symbol EXELIXIS, INC. [EXEL]											of Reporting able) r (give title	g Pers	on(s) to Issu 10% Ow Other (s	ner
	(Fi	•	(Middle)			of Earlies 2020	st Trar	nsact	action (Month/Day/Year)						below)	EVP, Co	mme	below)	респу	
(Street) ALAME (City)	DA CA	A	94502 (Zip)		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - Nor	n-Deriv	vativ	e Se	curitie	es A	cqu	ired, I	Disp	osed o	f, o	r Ben	eficiall	y Owned				
Date			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		´	Code (Instr.			rities Acquired (A) and Of (D) (Instr. 3,			5. Amour Securitie Beneficia Owned F	s Ily	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct C	7. Nature of Indirect Beneficial Ownership	
									Ì	Code	v	Amount		(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		((Instr. 4)
Common Stock ⁽¹⁾			02/19	9/2020 ⁽²⁾					Α		35,00	0	A	\$0	121,	191 ⁽³⁾		D		
Common Stock			02/1	02/19/2020					M		5,000)	A	\$0	126	,191		D		
Common Stock			02/1	9/2020					S ⁽⁴⁾		5,000)	D	\$22	121,191			D		
Common Stock															23,	539		1 1	By spouse	
Common Stock															10,6	548 ⁽⁵⁾			3y 401(k)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	Code (Instr		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea				7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	e ercisable		expiration pate	Title		Amount or Number of Shares					
Option (right to buy)	\$1.7	02/19/2020			М		5,000		07/2	20/2015 ⁽	6) 0	09/18/2021 Common Stock		5,000	\$0	35,000		D		

Explanation of Responses:

- 1. Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.
- 2. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2021 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.
- 3. Includes 72,614 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- 4. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2019.
- 5. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 19, 2020.
- 6. The option, representing the right to purchase a total of 120,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

Remarks:

/s/ Jennifer Drimmer Rokovich, 02/21/2020

** Signature of Reporting Person

Attorney in Fact

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.